IMPLICATIONS OF STRONG AND WEAK RECOM-MENDATIONS FOR CLINICIAN USERS OF AASM CLINICAL PRACTICE GUIDELINES

Strong Recommendation (We recommend…)
Almost all patients should receive the recommended course of action. Adherence to this recommendation could be used as a quality criterion or performance indicator.
Weak
Recommendation (We suggest…) Different choices will be appropriate for different patients, and the clinician must help each patient arrive at a management decision consistent with her or his values and preferences.
The ultimate judgment regarding the suitability of any specific recommendation must be made by the clinician. • Wake After Sleep Onset: Mean reduction was 25 minutes greater, compared to placebo (95% CI: 18 to 33 minute reduction)
RECOMMENDED FOR TREATING SLEEP ONSET
• Quality of Sleep: Moderate 1 improvement in quality of sleep, compared to placebo* This recommendation is based on trials of 10 mg doses of zolpidem.
⊕⊝⊝⊝ B>H
NOT RECOMMENDED FOR TREATING INSOMNIA
We suggest that clinicians not use the following drugs for the treatment of sleep onset or sleep maintenance insomnia (versus no treatment) in adults: Diphenhydramine, Melatonin, Tiagabine, Trazodone, L-tryptophan, Valerian. (Weak)
